Intravenous human immunoglobulin treatment of serum from HLA-sensitized patients in kidney transplantation

References

• Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–1730
   PubMed Web of Science ®Google Scholar
• Zachary AA, Leffell MS. Barriers to successful transplantation of the sensitized patient. Expert Rev Clin Immunol. 2010;6(3):449–460
   PubMed Web of Science ®Google Scholar
• Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol. 2010;6(5):297–306
   PubMedGoogle Scholar
• Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45(4):658–666
   PubMed Web of Science ®Google Scholar
• Grafals M, Chandraker A. New approaches for desensitization strategies prior to kidney transplantation. Am J Kidney Dis. 2009;53(3):370–372
   PubMedGoogle Scholar
• Süsal C, Morath C. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens. 2011;77(3):177–186
   PubMedGoogle Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–251
   PubMed Web of Science ®Google Scholar
• Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006;46(5):741–753
   PubMedGoogle Scholar
• Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6(3):459–466
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol. 2011;7(3):341–348
   PubMed Web of Science ®Google Scholar
• Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2(8):758–760
   PubMed Web of Science ®Google Scholar
• Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76(4):631–636
   PubMedGoogle Scholar
• Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107(4):387–393
   PubMed Web of Science ®Google Scholar
• Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001;108(suppl 4):S95–S98
   PubMedGoogle Scholar
• Heidt S, Roelen DL, Eijsink C, Eikmans M, Claas FHJ, Mulder A. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol. 2009;158(1):99–105
   PubMedGoogle Scholar
• Chamat S, Miquel C, Fisson S, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111(2):715–722
   PubMedGoogle Scholar
• Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokinedependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol. 1994;73(2):180–186
   PubMedGoogle Scholar
• MacMillan HF, Lee T, Issekutz AC. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. Clin Immunol. 2009;132(2):222–233
   PubMed Web of Science ®Google Scholar
• Minucci PB, Grimaldi V, Casamassimi A, et al. Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study. Exp Clin Transplant. 2011;9(6):381–386
   PubMedGoogle Scholar
• Jordan SC, Reinsmoen N, Lai CH, Vo A. Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discov Med. 2012;13(70):235–245
   PubMedGoogle Scholar
• Reinsmoen NL, Lai CH, Vo A, Jordan SC. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med. 2012;13(71):267–273
   PubMed Web of Science ®Google Scholar
• Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc. 2006;117:199–211; discussion 211
   PubMedGoogle Scholar
• Huh KH, Kim BS, Yang J, et al. Kidney transplantation after desensitization in sensitized patients: a Korean National Audit. Int Urol Nephrol. 2012;44(5):1549–1557
   PubMedGoogle Scholar
• Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIG). A potential tool for transplantation of immunized patients. Transplantation. 1993;56(2):335–337
   PubMedGoogle Scholar
• Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994;57(4):553–562
   PubMedGoogle Scholar
• Nair V, Sawinski D, Akalin E, et al. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant. 2012;26(3):E261–E268
   PubMedGoogle Scholar
• Wassmuth R, Hauser IA, Schuler K, et al. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation. 2001;71(10):1436–1442
   PubMedGoogle Scholar
• Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant. 2005;5(11):2786–2790
   PubMedGoogle Scholar
• Urra JM, de la Torre M, Alcázar R, et al. Variable in vitro inhibition of HLA-specific alloantibody-mediated cytotoxicity by intravenous human immunoglobulin. Transplant Proc. 1998;30(8):4177–4179
   PubMedGoogle Scholar
• Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64(4):1120–1125
   PubMedGoogle Scholar
• Mahmoud KM, Sobh MA, El-Shenawy F, et al. Can intravenous immunoglobulin and simvastatin solve the problem of sensitization in renal transplant candidates? Int Urol Nephrol. 2007;39(3):979–981
   PubMedGoogle Scholar
• Hyun J, Park KD, Yoo Y, et al. Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. Transplant Proc. 2012;44(1):222–225
   PubMedGoogle Scholar